Validation of a screening instrument for nephrogenic systemic fibrosis

Arthritis Care and Research

Volumn 65, Issue 4, 2013, Pages 637-642

  Lima, Xinaida Taligare ^a   Alora Palli, Maria Beatrice ^a   Kimball, Alexandra Boer ^a   Kay, Jonathan ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MALE; NEPHROGENIC SYSTEMIC FIBROSIS; PILOT STUDY; PREDICTIVE VALUE; QUESTIONNAIRE; RECEIVER OPERATING CHARACTERISTIC; SCREENING TEST; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SKIN FIBROSIS; SKIN MANIFESTATION; VALIDITY;

CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; PILOT PROJECTS; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS;

EID: 84875749318     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21877     Document Type: Article

References (26)

1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE,. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356: 1000-1.
2. Jimenez SA, Artlett CM, Sandorfi N, Derk C, Latinis K, Sawaya H, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor β1 expression in affected skin. Arthritis Rheum 2004; 50: 2660-6.
3. Kay J, Bazari H, Avery LL, Koreishi AF,. Case records of the Massachusetts General Hospital, case 6-2008: a 46-year-old woman with renal failure and stiffness of the joints and skin. N Engl J Med 2008; 358: 827-38.
4. Koreishi AF, Nazarian RM, Saenz AJ, Klepeis VE, McDonald AG, Farris AB, et al. Nephrogenic systemic fibrosis: a pathologic study of autopsy cases. Arch Pathol Lab Med 2009; 133: 1943-8.
5. Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA,. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 2006; 35: 238-49.
6. Sanyal S, Marckmann P, Scherer S, Abraham JL,. Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis: an autopsy-based review. Nephrol Dial Transplant 2011; 26: 3616-26.
7. Ting WW, Stone MS, Madison KC, Kurtz K,. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003; 139: 903-6.
8. Grobner T,. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21: 1104-8.
9. Todd DJ, Kagan A, Chibnik LB, Kay J,. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 2007; 56: 3433-41.
10. Kay J, Czirjak L,. Gadolinium and systemic fibrosis: guilt by association. Ann Rheum Dis 2010; 69: 1895-7.
11. Abujudeh HH, Kaewlai R, Kagan A, Chibnik LB, Nazarian RM, High WA, et al. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Radiology 2009; 253: 81-9.
12. Boyd AS, Zic JA, Abraham JL,. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007; 56: 27-30.
13. High WA, Ayers RA, Chandler J, Zito G, Cowper SE,. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56: 21-6.
14. Thakral C, Abraham JL,. Gadolinium-induced nephrogenic systemic fibrosis is associated with insoluble Gd deposits in tissues: in vivo transmetallation confirmed by microanalysis. J Cutan Pathol 2009; 36: 1244-54.
15. Bernstein EJ, Kay J,. Nephrogenic systemic fibrosis: a fibrosing disorder induced by gadolinium exposure. Int J Adv Rheumatol 2011; 9: 123-33.
16. Girardi M, Kay J, Elston DM, Leboit PE, Abu-Alfa A, Cowper SE,. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol 2011; 65: 1095-106.
17. Saxena SK, Sharma M, Patel M, Oreopoulos D,. Nephrogenic systemic fibrosis: an emerging entity. Int Urol Nephrol 2008; 40: 715-24.
18. Kay J, High WA,. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 2008; 58: 2543-8.
19. Prince MR, Zhang H, Morris M, MacGregor JL, Grossman ME, Silberzweig J, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 2008; 248: 807-16.
20. Rydahl C, Thomsen HS, Marckmann P,. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 2008; 43: 141-4.
21. McGee S,. Simplifying likelihood ratios. J Gen Intern Med 2002; 17: 646-9.
22. Nunnally JC,. Psychometric theory. 2nd ed. New York: McGraw-Hill; 1978.
23. Altun E, Martin DR, Wertman R, Lugo-Somolinos A, Fuller ER III, Semelka RC,. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy. Report from two US universities. Radiology 2009; 253: 689-96.
24. Wang Y, Alkasab TK, Narin O, Nazarian RM, Kaewlai R, Kay J, et al. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology 2011; 260: 105-11.
25. Thomsen HS,. Nephrogenic systemic fibrosis: history and epidemiology. Radiol Clin North Am 2009; 47: 827-31.
26. Lebiedz-Odrobina D, Kay J,. Rheumatic manifestations of diabetes mellitus. Rheum Dis Clin North Am 2010; 36: 681-99.